Drug repositioning : (Record no. 19652)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 06949cam a2200805Ma 4500 |
001 - CONTROL NUMBER | |
control field | ocn802068199 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | OCoLC |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20230823095528.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION | |
fixed length control field | m o d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr |n||||||||| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 111025s2012 njua ob 001 0 eng d |
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER | |
Canceled/invalid LC control number | 2011044253 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | CDX |
Language of cataloging | eng |
Description conventions | pn |
Transcribing agency | CDX |
Modifying agency | OCLCO |
-- | E7B |
-- | OCLCQ |
-- | OSU |
-- | OCLCQ |
-- | OCLCF |
-- | NLGGC |
-- | DG1 |
-- | CUS |
-- | OHI |
-- | RECBK |
-- | OCLCQ |
-- | EBLCP |
-- | N$T |
-- | YDXCP |
-- | DEBSZ |
-- | OCLCQ |
-- | COO |
-- | OCLCQ |
-- | DEBBG |
-- | AZK |
-- | LOA |
-- | OCLCO |
-- | OCLCA |
019 ## - | |
-- | 793103971 |
-- | 795120559 |
-- | 864909734 |
-- | 961530929 |
-- | 962709413 |
-- | 966211549 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 9780470878279 |
Qualifying information | (hbk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 0470878274 |
Qualifying information | (hbk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 9781118274408 |
Qualifying information | (electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 1118274407 |
Qualifying information | (electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 9781118274392 |
Qualifying information | (electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 1118274393 |
Qualifying information | (electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 9781118274378 |
Qualifying information | (electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
ISBN | 1118274377 |
Qualifying information | (electronic bk.) |
024 8# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 9786613673718 |
028 01 - PUBLISHER NUMBER | |
Publisher number | EB00063228 |
Source | Recorded Books |
029 1# - (OCLC) | |
OCLC library identifier | AU@ |
System control number | 000049595380 |
029 1# - (OCLC) | |
OCLC library identifier | AU@ |
System control number | 000052905589 |
029 1# - (OCLC) | |
OCLC library identifier | DEBSZ |
System control number | 431150141 |
029 1# - (OCLC) | |
OCLC library identifier | DKDLA |
System control number | 820120-katalog:000599886 |
029 1# - (OCLC) | |
OCLC library identifier | GBVCP |
System control number | 790037092 |
029 1# - (OCLC) | |
OCLC library identifier | NLGGC |
System control number | 35648761X |
029 1# - (OCLC) | |
OCLC library identifier | NZ1 |
System control number | 14976581 |
029 1# - (OCLC) | |
OCLC library identifier | DEBBG |
System control number | BV043394928 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (OCoLC)802068199 |
Canceled/invalid control number | (OCoLC)793103971 |
-- | (OCoLC)795120559 |
-- | (OCoLC)864909734 |
-- | (OCoLC)961530929 |
-- | (OCoLC)962709413 |
-- | (OCoLC)966211549 |
037 ## - SOURCE OF ACQUISITION | |
Stock number | 367371 |
Source of stock number/acquisition | MIL |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | RM301.25 |
Item number | .D78 2012eb |
060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
Classification number | QV 55 |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | BUS |
Subject category code subdivision | 070130 |
Source | bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 338.4/76151 |
Edition number | 23 |
049 ## - LOCAL HOLDINGS (OCLC) | |
Holding library | MAIN |
245 00 - TITLE STATEMENT | |
Title | Drug repositioning : |
Remainder of title | bringing new life to shelved assets and existing drugs / |
Statement of responsibility, etc | edited by Michael J. Barratt, Donald E. Frail. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Place of publication, distribution, etc | Hoboken, N.J. : |
Name of publisher, distributor, etc | Wiley, |
Date of publication, distribution, etc | ©2012. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 1 online resource (xx, 477 pages) : |
Other physical details | illustrations |
336 ## - | |
-- | text |
-- | txt |
-- | rdacontent |
337 ## - | |
-- | computer |
-- | c |
-- | rdamedia |
338 ## - | |
-- | online resource |
-- | cr |
-- | rdacarrier |
347 ## - | |
-- | data file |
-- | rda |
380 ## - | |
-- | Bibliography |
504 ## - BIBLIOGRAPHY, ETC. NOTE | |
Bibliography, etc | Includes bibliographical references and index. |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Drug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs / John Arrowsmith and Richard Harrison -- Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs / Donald E. Frail and Michael J. Barratt -- Clinical and operational considerations in repositioning marketed drugs and drug candidates / Damian O'Connell, David J. Sequeira, and Maria L. Miller -- Regulatory considerations and strategies for drug repositioning / Ken Phelps -- Computational and bioinformatic strategies for drug repositioning / Richard Mazzarella and Craig Webb -- Mining scientific and clinical databases to identify novel uses for existing drugs / Christos Andronis [and others] -- Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics, and molecular modeling-based approaches / Li Xie [and others] -- Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs / Margaret S. Lee -- Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates / Michael S. Saporito, Christopher A. Lipinski, and Andrew G. Reaume -- Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies / Adam J. Morgan [and others] -- Repurposing drugs for tropical diseases : case studies and open-source screening initiatives / Curtis R. Chong -- Drug repositioning efforts by nonprofit foundations -- Business development strategies in the repositioning industry / Aris Persidis and Elizabeth T. Stark -- A case study in drug repositioning : Sosei / Akinori Mochizuki and Makiko Aoyama. |
588 ## - | |
-- | Print version record. |
520 ## - SUMMARY, ETC. | |
Summary, etc | BThe how's and why's of successful drug repositioning /b/ Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy./ iDrug Repositioning/i is divided into three parts:/ ulli bPart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, /b examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs./ /lili bPart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, /b sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents./ /lili bPart 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry/b, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return./ /li/ul The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits./ With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development. |
526 ## - STUDY PROGRAM INFORMATION NOTE | |
Department | Life Sciences |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Drug development. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Pharmaceutical industry. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Drug Repositioning. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Computational Biology |
General subdivision | methods. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Drug Industry |
General subdivision | economics. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Pharmaceutical Preparations |
General subdivision | economics. |
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Medical. |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | MEDICAL |
General subdivision | Pharmacology. |
Source of heading or term | bisacsh |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Drug development. |
Source of heading or term | fast |
-- | (OCoLC)fst00898670 |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Pharmaceutical industry. |
Source of heading or term | fast |
-- | (OCoLC)fst01060129 |
655 #4 - INDEX TERM--GENRE/FORM | |
Genre/form data or focus term | Electronic books. |
655 #7 - INDEX TERM--GENRE/FORM | |
Genre/form data or focus term | Electronic books. |
Source of term | local |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Barratt, Michael J. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Frail, Donald. |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Display text | Print version: |
International Standard Book Number | 9786613673718 |
Record control number | (OCoLC)758943206 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="http://dx.doi.org/10.1002/9781118274408">http://dx.doi.org/10.1002/9781118274408</a> |
Public note | Wiley Online Library |
994 ## - | |
-- | 92 |
-- | DG1 |
No items available.